Sergio Cifuentes-Canaval, Medical Oncologist at Las Américas Auna Clinic, shared on LinkedIn:
“Does ctDNA during adjuvant endocrine therapy guide action yet, or is it still a finding without one?
TRAK-ER (Annals of Oncology) is a prospective multicentre study in high-risk ER+/HER2- early breast cancer, with ctDNA every 3 months for up to 3 years. 912 patients started surveillance and 12.0% had detectable ctDNA. With first-test detection, 65.9% already had radiological recurrence; later, 26.6%.

What it supports
Molecular relapse is common and tracks with nodal burden and grade.
What it does not establish
That acting on it improves outcomes. The randomised phase (palbociclib plus fulvestrant) is still ongoing.
For LATAM
European cohort, and tumour-informed assays have limited access in the region. As a hypothesis, its near-term place is research.
Would you use serial ctDNA outside a trial?”
Title: Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study
Authors: N. Cunningham, C. Swift, R.J. Cutts, K. Thomas, S. Sardo Infirri, F. Dalenc, F. Le Du, I.R. Macpherson, C. O’Brien, C. Palmieri, P. Schmid, F. Legrand, J. Lemonnier, R.D. Daber, J. Zhao, E. Gauthier, AFC Okines, D. Lee, I. Garcia-Murillas, M. Robert, F. Andre, N.C. Turner
Continue exploring:
